Search Results - "MPINDI, John Patrick"

High-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cells by Hongisto, Vesa, Jernström, Sandra, Fey, Vidal, Mpindi, John-Patrick, Kleivi Sahlberg, Kristine, Kallioniemi, Olli, Perälä, Merja

“…The traditional method for studying cancer in vitro is to grow immortalized cancer cells in two-dimensional monolayers on plastic. However, many cellular…”
Get full text

A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses by Härmä, Ville, Virtanen, Johannes, Mäkelä, Rami, Happonen, Antti, Mpindi, John-Patrick, Knuuttila, Matias, Kohonen, Pekka, Lötjönen, Jyrki, Kallioniemi, Olli, Nees, Matthias

“…Prostate epithelial cells from both normal and cancer tissues, grown in three-dimensional (3D) culture as spheroids, represent promising in vitro models for…”
Get full text

Clinical relevance of integrin alpha 4 in gastrointestinal stromal tumours by Pulkka, Olli‐Pekka, Mpindi, John‐Patrick, Tynninen, Olli, Nilsson, Bengt, Kallioniemi, Olli, Sihto, Harri, Joensuu, Heikki

“…The molecular mechanisms for the dissemination and metastasis of gastrointestinal stromal tumours (GIST) are incompletely understood. The purpose of the study…”
Get full text

High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion by Lehtinen, Laura, Ketola, Kirsi, Mäkelä, Rami, Mpindi, John-Patrick, Viitala, Miro, Kallioniemi, Olli, Iljin, Kristiina

“…Vimentin is an intermediate filament protein, with a key role in the epithelial to mesenchymal transition as well as cell invasion, and it is often upregulated…”
Get full text

Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues by Kilpinen, Sami, Autio, Reija, Ojala, Kalle, Iljin, Kristiina, Bucher, Elmar, Sara, Henri, Pisto, Tommi, Saarela, Matti, Skotheim, Rolf I, Björkman, Mari, Mpindi, John-Patrick, Haapa-Paananen, Saija, Vainio, Paula, Edgren, Henrik, Wolf, Maija, Astola, Jaakko, Nees, Matthias, Hautaniemi, Sampsa, Kallioniemi, Olli

“…Our knowledge on tissue- and disease-specific functions of human genes is rather limited and highly context-specific. Here, we have developed a method for the…”
Get full text

Arachidonic Acid Pathway Members PLA2G7 , HPGD , EPHX2 , and CYP4F8 Identified as Putative Novel Therapeutic Targets in Prostate Cancer by Vainio, Paula, Gupta, Santosh, Ketola, Kirsi, Mirtti, Tuomas, Mpindi, John-Patrick, Kohonen, Pekka, Fey, Vidal, Perälä, Merja, Smit, Frank, Verhaegh, Gerald, Schalken, Jack, Alanen, Kalle A, Kallioniemi, Olli, Iljin, Kristiina

“…The arachidonic acid and prostaglandin pathway has been implicated in prostate carcinogenesis, but comprehensive studies of the individual members in this key…”
Get full text

Anagrelide for Gastrointestinal Stromal Tumor by Pulkka, Olli-Pekka, Gebreyohannes, Yemarshet K, Wozniak, Agnieszka, Mpindi, John-Patrick, Tynninen, Olli, Icay, Katherine, Cervera, Alejandra, Keskitalo, Salla, Murumägi, Astrid, Kulesskiy, Evgeny, Laaksonen, Maria, Wennerberg, Krister, Varjosalo, Markku, Laakkonen, Pirjo, Lehtonen, Rainer, Hautaniemi, Sampsa, Kallioniemi, Olli, Schöffski, Patrick, Sihto, Harri, Joensuu, Heikki

“…Gastrointestinal stromal tumor (GIST) is a common type of soft-tissue sarcoma. Imatinib, an inhibitor of KIT, platelet-derived growth factor receptor alpha…”
Get full text

ITGB1-dependent upregulation of Caveolin-1 switches TGFβ signalling from tumour-suppressive to oncogenic in prostate cancer by Pellinen, Teijo, Blom, Sami, Sánchez, Sara, Välimäki, Katja, Mpindi, John-Patrick, Azegrouz, Hind, Strippoli, Raffaele, Nieto, Raquel, Vitón, Mariano, Palacios, Irene, Turkki, Riku, Wang, Yinhai, Sánchez-Alvarez, Miguel, Nordling, Stig, Bützow, Anna, Mirtti, Tuomas, Rannikko, Antti, Montoya, María C., Kallioniemi, Olli, del Pozo, Miguel A.

“…Caveolin-1 (CAV1) is over-expressed in prostate cancer (PCa) and is associated with adverse prognosis, but the molecular mechanisms linking CAV1 expression to…”
Get full text

High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer by Vainio, Paula, Mpindi, John-Patrick, Kohonen, Pekka, Fey, Vidal, Mirtti, Tuomas, Alanen, Kalle A, Perälä, Merja, Kallioniemi, Olli, Iljin, Kristiina

“…Prostate cancer is a heterogeneous group of diseases and there is a need for more efficient and targeted methods of treatment. In this study, the potential of…”
Get full text

REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker by Lehtinen, Laura, Vesterkvist, Pia, Roering, Pia, Korpela, Taina, Hattara, Liisa, Kaipio, Katja, Mpindi, John-Patrick, Hynninen, Johanna, Auranen, Annika, Davidson, Ben, Haglund, Caj, Iljin, Kristiina, Grenman, Seija, Siitari, Harri, Carpen, Olli

“…Preoperative diagnostics of ovarian neoplasms rely on ultrasound imaging and the serum biomarkers CA125 and HE4. However, these markers may be elevated in…”
Get full text

High miR-30 Expression Associates with Improved Breast Cancer Patient Survival and Treatment Outcome by Jamshidi, Maral, Fagerholm, Rainer, Muranen, Taru A., Kaur, Sippy, Potdar, Swapnil, Khan, Sofia, Netti, Eliisa, Mpindi, John-Patrick, Yadav, Bhagwan, Kiiski, Johanna I., Aittomäki, Kristiina, Heikkilä, Päivi, Saarela, Jani, Bützow, Ralf, Blomqvist, Carl, Nevanlinna, Heli

“…Deregulated miRNA expression has been suggested in several stages of breast cancer pathogenesis. We have studied the miR-30 family, in particular miR-30d, in…”
Get full text

Plasticity of blood- and lymphatic endothelial cells and marker identification by Keuschnigg, Johannes, Karinen, Sirkku, Auvinen, Kaisa, Irjala, Heikki, Mpindi, John-Patrick, Kallioniemi, Olli, Hautaniemi, Sampsa, Jalkanen, Sirpa, Salmi, Marko

“…The distinction between lymphatic and blood vessels is biologically fundamental. Here we wanted to rigorously analyze the universal applicability of vascular…”
Get full text

A cell spot microarray method for production of high density siRNA transfection microarrays by Rantala, Juha K, Mäkelä, Rami, Aaltola, Anna-Riina, Laasola, Petra, Mpindi, John-Patrick, Nees, Matthias, Saviranta, Petri, Kallioniemi, Olli

“…High-throughput RNAi screening is widely applied in biological research, but remains expensive, infrastructure-intensive and conversion of many assays to HTS…”
Get full text

Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer by Kangaspeska, Sara, Hultsch, Susanne, Jaiswal, Alok, Edgren, Henrik, Mpindi, John-Patrick, Eldfors, Samuli, Brück, Oscar, Aittokallio, Tero, Kallioniemi, Olli

“…The estrogen receptor (ER) inhibitor tamoxifen reduces breast cancer mortality by 31 % and has served as the standard treatment for ER-positive breast cancers…”
Get full text

Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancer by Vainio, Paula, Wolf, Maija, Edgren, Henrik, He, Tao, Kohonen, Pekka, Mpindi, John-Patrick, Smit, Frank, Verhaegh, Gerald, Schalken, Jack, Perälä, Merja, Iljin, Kristiina, Kallioniemi, Olli

“…BACKGROUND Castration‐resistant prostate cancer (CRPC) represents a therapeutic challenge for current medications. METHODS In order to explore the molecular…”
Get full text

Androgen receptor‐interacting protein HSPBAP1 facilitates growth of prostate cancer cells in androgen‐deficient conditions by Saeed, Khalid, Östling, Päivi, Björkman, Mari, Mirtti, Tuomas, Alanen, Kalle, Vesterinen, Tiina, Sankila, Anna, Lundin, Johan, Lundin, Mikael, Rannikko, Antti, Nordling, Stig, Mpindi, John‐Patrick, Kohonen, Pekka, Iljin, Kristiina, Kallioniemi, Olli, Rantala, Juha K.

“…Hormonal therapies targeting androgen receptor (AR) are effective in prostate cancer (PCa), but often the cancers progress to fatal castrate‐resistant disease…”
Get full text

Breeze: an integrated quality control and data analysis application for high-throughput drug screening by Potdar, Swapnil, Ianevski, Aleksandr, Mpindi, John-Patrick, Bychkov, Dmitrii, Fiere, Clément, Ianevski, Philipp, Yadav, Bhagwan, Wennerberg, Krister, Aittokallio, Tero, Kallioniemi, Olli, Saarela, Jani, Östling, Päivi

“…Abstract Summary High-throughput screening (HTS) enables systematic testing of thousands of chemical compounds for potential use as investigational and…”
Get full text

A community effort to assess and improve drug sensitivity prediction algorithms by Costello, James C, Heiser, Laura M, Georgii, Elisabeth, Gönen, Mehmet, Menden, Michael P, Wang, Nicholas J, Bansal, Mukesh, Ammad-ud-din, Muhammad, Hintsanen, Petteri, Khan, Suleiman A, Mpindi, John-Patrick, Kallioniemi, Olli, Honkela, Antti, Aittokallio, Tero, Wennerberg, Krister, Collins, James J, Gallahan, Dan, Singer, Dinah, Saez-Rodriguez, Julio, Kaski, Samuel, Gray, Joe W, Stolovitzky, Gustavo

“…A community of researchers report the lessons learned from applying 44 algorithms to predict drug sensitivity in cancer cell lines using genomic, epigenetic…”
Get full text

A community computational challenge to predict the activity of pairs of compounds by Bansal, Mukesh, Yang, Jichen, Karan, Charles, Menden, Michael P, Costello, James C, Tang, Hao, Xiao, Guanghua, Li, Yajuan, Allen, Jeffrey, Zhong, Rui, Chen, Beibei, Kim, Minsoo, Wang, Tao, Heiser, Laura M, Realubit, Ronald, Mattioli, Michela, Alvarez, Mariano J, Shen, Yao, Gallahan, Daniel, Singer, Dinah, Saez-Rodriguez, Julio, Xie, Yang, Stolovitzky, Gustavo, Califano, Andrea

“…A community computational challenge generates algorithms to predict activity of drug combinations. Recent therapeutic successes have renewed interest in drug…”
Get full text

FZD4 as a Mediator of ERG Oncogene―Induced WNT Signaling and Epithelial-to-Mesenchymal Transition in Human Prostate Cancer Cells by GUPTA, Santosh, ILJIN, Kristiina, SARA, Henri, MPINDI, John Patrick, MIRTTI, Tuomas, VAINIO, Paula, RANTALA, Juha, ALANEN, Kalle, NEES, Matthias, KALLIONIEMI, Olli

“…TMPRSS2-ERG and other gene fusions involving ETS factors and genes with strong promoter elements are common in prostate cancer. Although ERG activation has…”
Get full text